1. Home
  2. |Insights
  3. |The FDA Reverses Course and Authorizes the Importation of Non-NIOSH Approved Respirators Manufactured in China

The FDA Reverses Course and Authorizes the Importation of Non-NIOSH Approved Respirators Manufactured in China

Client Alert | 2 min read | 04.06.20

In response to the current public health crisis causing medical equipment shortages, on April 3, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) permitting the importation of non-NIOSH approved filtering face-piece respirators (FFRs) manufactured in China, including KN95 masks. In its original EUA from March 28, FDA had authorized importation of similar respirators from six other countries, but China was excluded, despite the Centers for Disease Control and Prevention’s (CDC’s) statement that KN95 masks are “expected to be suitable alternatives to provide protection during the COVID-19 response while supplies are short.” FDA’s new EUA aligns with the CDC’s recommendation. 

To qualify for the EUA and be eligible for importation, manufacturers of disposable non-NIOSH-approved FFRs manufactured in China must show that offered masks are authentic. Evidence of authenticity may include additional validation and review by FDA. Further, they must show that the offered masks:

  1. Are manufactured by an entity that holds one or more NIOSH approvals for other models of FFRs produced in accordance with the applicable standards of authorization in other countries that can be verified by FDA;
  2. Have regulatory authorization from a jurisdiction other than China that can be authenticated and verified by FDA; or
  3. Demonstrate acceptable performance to applicable testing standards as documented by test reports from a recognized independent test laboratory that can be verified by FDA.

FDA may ask a manufacturer requesting authorization for additional information if the agency needs to confirm eligibility based on the criteria listed above.

This new authorization is particularly significant as products which meet the criteria listed under EUAs are eligible for protections under the Public Readiness and Emergency Preparedness Act (PREP Act). The PREP Act grants immunity from liability against claims of loss which are caused by, arise out of, relate to, or result from the manufacture, distribution, administration, or use of designated “Covered Countermeasures.” Non-NIOSH approved FFRs which fully adhere to requirements under the applicable EUA would fall under the category of “drugs, devices, or biological products authorized for emergency use,” and would therefore be considered Covered Countermeasures for the purposes of the PREP Act. Certain limitations apply to PREP Act immunity, however, as is discussed more fully in our prior client alert.

Contacts

Insights

Client Alert | 5 min read | 08.21.26

FTC Proposes Enforcement Policy Statement on Personalized Pricing: What Businesses Need to Know

On August 19, 2026, the Federal Trade Commission (FTC) announced a proposed Enforcement Policy Statement on personalized pricing — the practice of companies using consumers’ personal data to set individualized prices, discounts, coupons, or other incentives. The proposed statement, which is open for public comment for 30 days following publication in the Federal Register, marks a major step up in the FTC’s focus on data-driven pricing strategies and puts businesses across industries on notice that undisclosed or inadequately disclosed personalized pricing will not be tolerated. Importantly, while the proposed statement is not a binding legal requirement and does not create new legal obligations, it serves as an enforcement warning that the FTC is prepared to use its existing enforcement authority under Section 5 of the FTC Act (Section 5) and is also a potential harbinger of rulemaking. Businesses that engage in — or are considering — personalized pricing should carefully assess their disclosure practices and data collection procedures against the standards articulated in this statement....